Update on endocrine hypertension;Données récentes sur l'hypertension endocrine

Annales d'Endocrinologie

Volumn 73, Issue SUPPL.1, 2012, Pages

  Al Salameh, A ^a,b   Cohen, R ^a,b   Chanson, P ^c,d   Plouin, P F ^e,f  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Endocrine hypertension; Pheochromocytoma; Primary hyperaldosteronism

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER;

ADENOMA; ARTICLE; BILATERAL IDIOPATHIC HYPERALDOSTERONISM; CARDIOVASCULAR RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; ESSENTIAL HYPERTENSION; GENE; GENETIC DISORDER; GENOTYPE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KCNJ5 GENE; PATHOPHYSIOLOGY; PATIENT CARE; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; RARE DISEASE; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL ADENOMA; ALDOSTERONE; CARDIOVASCULAR DISEASES; ENDOCRINE SYSTEM DISEASES; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MUTATION; PHEOCHROMOCYTOMA; RISK FACTORS;

EID: 84867913632     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4266(12)70012-4     Document Type: Article

References (60)

1. Ostchega Y., Yoon S.S., Hughes J., Louis T. Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. NCHS Data Brief 2008, 3:1-8.
2. Young W.F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007, 66:607-618.
3. Carey R.M. Role of K (+) channels in the pathophysiology of primary aldosteronism. Hypertension 2012, 59:534-536.
4. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
5. Funder J.W., Carey R.M., Fardella C., Gomez-Sanchez C.E., Mantero F., Stowasser M., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266-3281.
6. Rossi G.P., Seccia T.M., Pessina A.C. Primary aldosteronism - part I: prevalence, screening, and selection of cases for adrenal vein sampling. J Nephrol 2008, 21:447-454.
7. Solar M., Malirova E., Ballon M., Pelouch R., Ceral J. Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patients. Eur J Endocrinol 2012, 166:679-686.
8. Amar L., Gimenez-Roqueplo A.P., Rossignol P., Plouin P.F. Hyperaldostéronisme primaire. Traité d'endocrinologie 2007, 374-379. Flammarion-Médecine-Sciences, Paris. P. Chanson, J. Young (Eds.).
9. Nanba K., Tamanaha T., Nakao K., Kawashima S.T., Usui T., Tagami T., et al. Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab 2012, 97:1688-1694.
10. Young W.F., Stanson A.W., Thompson G.B., Grant C.S., Farley D.R., van Heerden J.A. Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227-1235.
11. Kempers M.J., Lenders J.W., van Outheusden L., van der Wilt G.J., Schultze Kool L.J., Hermus A.R., et al. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009, 151:329-337.
12. Burton T.J., Mackenzie I.S., Balan K., Koo B., Bird N., Soloviev D.V., et al. Evaluation of the sensitivity and specificity of (11) C-metomidate positron emission tomography (PET) -CT for lateralizing aldosterone secretion by Conn's adenomas. J Clin Endocrinol Metab 2012, 97:100-109.
13. Rossi G.P., Barisa M., Allolio B., Auchus R.J., Amar L., Cohen D., et al. The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab 2012, 97:1606-1614.
14. Monticone S., Satoh F., Giacchetti G., Viola A., Morimoto R., Kudo M., et al. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension 2012, 59:840-846.
15. Choi M., Scholl U.I., Yue P., Björklund P., Zhao B., Nelson-Williams C., et al. K+ channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science 2011, 331:768-772.
16. Azizan E.A., Murthy M., Stowasser M., Gordon R., Kowalski B., Xu S., et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012, 59:587-591.
17. Boulkroun S., Beuschlein F., Rossi G.P., Golib-Dzib J.F., Fischer E., Amar L., et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012, 59:592-598.
18. Taguchi R., Yamada M., Nakajima Y., Satoh T., Hashimoto K., Shibusawa N., et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012, 97:1311-1319.
19. Gomez-Sanchez C.E., Gomez-Sanchez E.P. Mutations of the potassium channel KCNJ5 causing aldosterone-producing adenomas: one or two hits ?. Hypertension 2012, 59:196-197.
20. Funder J.W. The genetics of primary aldosteronism: chapter two. Hypertension 2012, 59:537-538.
21. Oki K., Plonczynski M.W., Luis Lam M., Gomez-Sanchez E.P., Gomez-Sanchez C.E. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012, 153:1774-1782.
22. Monticone S., Hattangady N.G., Nishimoto K., Mantero F., Rubin B., Cicala M.V., et al. Effect of KCNJ5 Mutations on Gene Expression in Aldosterone-Producing Adenomas and Adrenocortical Cells. J Clin Endocrinol Metab 2012, 97:E1567-E1572.
23. Williams T.A., Monticone S., Crudo V., Warth R., Veglio F., Mulatero P. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calciuminduced apoptosis. Hypertension 2012, 59:833-839.
24. Zennaro M.C. Primary aldosteronism takes (KCNJ) five!. Endocrinology 2012, 153:1575-1577.
25. Azizan E.A., Lam B.Y., Newhouse S.J., Zhou J., Kuc R.E., Clarke J., et al. Microarray, qPCR, and KCNJ5 sequencing of aldosteroneproducing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012, 97:E819-E829.
26. McMahon G.T., Dluhy R.G. Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metab 2004, 48:682-686.
27. Mulatero P., Tizzani D., Viola A., Bertello C., Monticone S., Mengozzi G., et al. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011, 58:797-803.
28. Funder J.W. Medicine. The genetics of primary aldosteronism. Science 2011, 331:685-686.
29. Mulatero P., Tauber P., Zennaro M.C., Monticone S., Lang K., Beuschlein F., et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension 2012, 59:235-240.
30. Charmandari E., Sertedaki A., Kino T., Merakou C., Hoffman D.A., Hatch M.M., et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012, 97:E1532-E1539.
31. Scholl U.I., Nelson-Williams C., Yue P., Grekin R., Wyatt R.J., Dillon M.J., et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012, 109:2533-2538.
32. Stowasser M. Update in primary aldosteronism. J Clin Endocrinol Metab 2009, 94:3623-3630.
33. Steichen O., Zinzindohoué F., Plouin P.F., Amar L. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review. Horm Metab Res 2012, 44:221-227.
34. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R., et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008, 168:80-85.
35. Fischer E., Beuschlein F., Degenhart C., Jung P., Bidlingmaier M., Reincke M. Spontaneous remission of idiopathic aldosteronism after long-term treatment with spironolactone: results from the German Conn's Registry. Clin Endocrinol (Oxf) 2012, 76:473-477.
36. Yoneda T., Demura M., Takata H., Kometani M., Karashima S., Yamagishi M., et al. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. J Clin Endocrinol Metab 2012, 97:1109-1113.
37. Parthasarathy H.K., Ménard J., White W.B., Young W.F., Williams G.H., Williams B., Ruilope L.M., McInnes G.T., Connell J.M., MacDonald T.M. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011, 29:980-990.
38. Amar L., Azizi M., Menard J., Peyrard S., Watson C., Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010, 56:831-838.
39. Sukor N. Endocrine hypertension-current understanding and comprehensive management review. Eur J Intern Med 2011, 22:433-440.
40. Shine B. Gene targeting through o-methylated catecholamine metabolite patterns. Clin Chem 2011, 57:361-362.
41. Kudva Y.C., Sawka A.M., Young W.F. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003, 88:4533-4539.
42. Lenders J.W., Pacak K., Walther M.M., Linehan W.M., Mannelli M., Friberg P., et al. Biochemical diagnosis of pheochromocytoma: which test is best ?. JAMA 2002, 287:1427-1434.
43. Lee G.R., Johnston P.C., Atkinson A.B., McKillop D., Auld P., Hunter S.J. A comparison of plasma-free metanephrines with plasma catecholamines in the investigation of suspected pheochromocytoma. J Hypertens 2011, 29:2422-2428.
44. Eisenhofer G., Lenders J.W., Timmers H., Mannelli M., Grebe S.K., Hofbauer L.C., et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clin Chem 2011, 57:411-420.
45. Eisenhofer G., Lenders J.W., Siegert G., Bornstein S.R., Friberg P., Milosevic D., et al. Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer 2012, 48:1739-1749.
46. Ilias I., Divgi C., Pacak K. Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 2011, 41:364-368.
47. Timmers H.J., Chen M.L., Carrasquillo J.A., Whatley M., Ling A., Havekes B., et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009, 94:4757-4767.
48. Timmers H.J., Chen M.L., Carrasquillo J.A., Whatley M., Ling A., Eisenhofer G., et al. Staging and functional characterization of pheochromocytoma and paraganglioma by18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 2012, 104:700-708.
49. Gimenez-Roqueplo A.P., Dahia P.L., Robledo M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 2012, 44:328-333.
50. Amar L., Gimenez-Roqueplo A.P., Hernigou A., Plouin P.F. Phéochromocytomes. Traité d'endocrinologie 2007, 380-386. Flammarion-Médecine-Sciences, Paris. P. Chanson, J. Young (Eds.).
51. Jafri M., Maher E.R. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol 2012, 166:151-158.
52. Mazzaglia P.J. Hereditary pheochromocytoma and paraganglioma. J Surg Oncol 2012, in press.
53. Korpershoek E., Favier J., Gaal J., Burnichon N., van Gessel B., Oudijk L., et al. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab 2011, 96:E1472-E1476.
54. Abermil N., Guillaud-Bataille M., Burnichon N., Venisse A., Manivet P., Guignat L., et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab 2012, 97:E805-E809.
55. Burnichon N., Cascón A., Schiavi F., Morales N.P., Comino-Méndez I., Abermil N., et al. MAX mutations cause hereditaryand sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 2012, 18:2828-2837.
56. Cascón A., Robledo M. MAX and MYC: A Heritable Breakup. Cancer Res 2012, 72:3119-3124.
57. Gimenez-Roqueplo A.P., Tischler A.S. Pheochromocytoma and Paraganglioma: progress on all fronts. Endocr Pathol 2012, 23:1-3.
58. Shao Y., Chen R., Shen Z.J., Teng Y., Huang P., Rui W.B., et al. Preoperative alpha blockade for normotensive pheochromocytoma: is it necessary ?. J Hypertens 2011, 29:2429-2432.
59. Lentschener C., Gaujoux S., Tesniere A., Dousset B. Point of controversy: perioperative care of patients undergoing pheochromocytoma removal-time for a reappraisal ?. Eur J Endocrinol 2011, 165:365-373.
60. Amar L., Fassnacht M., Gimenez-Roqueplo A.P., Januszewicz A., Prejbisz A., Timmers H., et al. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 2012, 44:385-389.